{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-120668","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2025-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.288295+00:00","generated_at":"2026-05-16T13:31:26.326238+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BiomX subsidiary BiomX Ltd files for insolvency; Phase 2b study discontinued","bullets":["Phase 2b study discontinued Dec 8 due to resource constraints exceeding available funds.","Dec 11: Board of BiomX Ltd authorized filing for insolvency proceedings in Israel.","Company evaluating strategic options; continues BX011 program via Adaptive Phage Therapeutics.","Limited financial resources cited as primary reason for study discontinuation and insolvency filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-120668","json":"https://secwatch.observer/filing/0001213900-25-120668.json","markdown":"https://secwatch.observer/filing/0001213900-25-120668.md","text":"https://secwatch.observer/filing/0001213900-25-120668.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/0001213900-25-120668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390025120668/ea0269336-8k_biomx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:31:26.326238+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001750155-26-000080","ticker":"CWBHF","company_name":"Charlotte's Web Holdings, Inc.","filed_at":"2026-06-01T21:13:23+00:00","headline":"Charlotte's Web appoints BAT GC to board, closes debt conversion & US$10M investment","event_type":"other_material","sec_items":["5.02","5.07","8.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001750155-26-000080","json":"https://secwatch.observer/filing/0001750155-26-000080.json","markdown":"https://secwatch.observer/filing/0001750155-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/0001750155-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750155/000175015526000080/cweb-20260528.htm"},"side_by_side_evidence":null},{"accession":"0001790340-26-000059","ticker":"IMRX","company_name":"Immuneering Corp","filed_at":"2026-06-01T20:51:53+00:00","headline":"Immuneering reports 17.3-month median OS in Phase 2a pancreatic trial of atebimetinib","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000059","json":"https://secwatch.observer/filing/0001790340-26-000059.json","markdown":"https://secwatch.observer/filing/0001790340-26-000059.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/0001790340-26-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000059/imrx-20260601.htm"},"side_by_side_evidence":null},{"accession":"0000798359-26-000057","ticker":"CSR","company_name":"CENTERSPACE","filed_at":"2026-06-01T20:30:13+00:00","headline":"Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000798359-26-000057","json":"https://secwatch.observer/filing/0000798359-26-000057.json","markdown":"https://secwatch.observer/filing/0000798359-26-000057.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001689548-26-000053","ticker":"PRAX","company_name":"Praxis Precision Medicines, Inc.","filed_at":"2026-06-01T20:28:49+00:00","headline":"Praxis Precision Medicines: Phase 2/3 vormatrigine study fails primary endpoint in focal seizures","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001689548-26-000053","json":"https://secwatch.observer/filing/0001689548-26-000053.json","markdown":"https://secwatch.observer/filing/0001689548-26-000053.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/0001689548-26-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000053/prax-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063500","ticker":"PLUR","company_name":"Pluri Inc.","filed_at":"2026-06-01T20:06:43+00:00","headline":"Pluri gets EIB nod for loan talks; no enforcement until July 3 on €20M maturing today","event_type":"other_material","sec_items":["8.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063500","json":"https://secwatch.observer/filing/0001213900-26-063500.json","markdown":"https://secwatch.observer/filing/0001213900-26-063500.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1158780/000121390026063500/0001213900-26-063500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1158780/000121390026063500/ea0292940-8k_pluri.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251394","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-01T20:05:16+00:00","headline":"Fulcrum Therapeutics discontinues pociredir program in SCD; initiates strategic review","event_type":"other_material","sec_items":["8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 8.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251394","json":"https://secwatch.observer/filing/0001193125-26-251394.json","markdown":"https://secwatch.observer/filing/0001193125-26-251394.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/0001193125-26-251394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526251394/fulc-20260601.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}